These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17002483)

  • 1. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis.
    Welsing PM; Severens JL; Hartman M; van Gestel AM; van Riel PL; Laan RF
    Pharmacoeconomics; 2006; 24(10):1011-20. PubMed ID: 17002483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic consequences of the progression of rheumatoid arthritis in Sweden.
    Kobelt G; Eberhardt K; Jönsson L; Jönsson B
    Arthritis Rheum; 1999 Feb; 42(2):347-56. PubMed ID: 10025930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
    Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
    Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):395-420. PubMed ID: 15853438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for monitoring joint inflammation in early rheumatoid arthritis.
    Nair SC; Welsing PM; Jacobs JW; van Laar JM; Rensen WH; Ardine de Wit G; Bijlsma JW; Lafeber FP
    Clin Exp Rheumatol; 2015; 33(6):831-8. PubMed ID: 26343274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.
    Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
    Arthritis Rheum; 2002 Sep; 46(9):2310-9. PubMed ID: 12355478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term morbidity, mortality, and economics of rheumatoid arthritis.
    Wong JB; Ramey DR; Singh G
    Arthritis Rheum; 2001 Dec; 44(12):2746-9. PubMed ID: 11762934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
    Konnopka A; Conrad K; Baerwald C; König HH
    Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.
    Gissel C; Götz G; Repp H
    Z Rheumatol; 2016 Dec; 75(10):1006-1015. PubMed ID: 27080399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
    Kobelt G
    Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.